CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases
CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an e...
Gespeichert in:
| Veröffentlicht in: | Life sciences (1973) 2020-10, Vol.259, p.118165-118165, Article 118165 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118165 |
|---|---|
| container_issue | |
| container_start_page | 118165 |
| container_title | Life sciences (1973) |
| container_volume | 259 |
| creator | Karimian, Ansar Gorjizadeh, Negar Alemi, Forough Asemi, Zatollah Azizian, Khalil Soleimanpour, Jafar Malakouti, Faezeh Targhazeh, Niloufar Majidinia, Maryam Yousefi, Bahman |
| description | CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
[Display omitted] |
| doi_str_mv | 10.1016/j.lfs.2020.118165 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429784646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320520309176</els_id><sourcerecordid>2429784646</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-f0528d420a25d814ee792f90ceed65836e837d641155cecad1ffb096546998dd3</originalsourceid><addsrcrecordid>eNqFkUFrFDEUx4MouFY_gLcBL15m-5JJMgk9yWK1UGhZ7TnE5EWzzE62SWah394s66kHewov_P5_eO9HyEcKawpUXu7WUyhrBqzNVFEpXpEVVaPuQQ70NVkBMN4PDMRb8q6UHQAIMQ4rst1sb37cby83tuhuTkecuvoHsz3gUqPrcrK-CymfPrua0dY9zrVLoZtxycnjb5wbXeMROx8L2oLlPXkT7FTww7_3gjxcf_25-d7f3n272Xy57d2gae0DCKY8Z2CZ8IpyxFGzoMEheinUIFENo5ecUiEcOutpCL9AS8Gl1sr74YJ8PvcecnpcsFSzj8XhNNkZ01IMExy4ppyrl1HO9Ki45LKhn56hu7TkuS3SCkHw1jfSRtEz5XIqJWMwhxz3Nj8ZCuYkxOxME2JOQsxZSMtcnTPYjnKMmE1xEWeHPmZ01fgU_5P-C3A9kXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2505414471</pqid></control><display><type>article</type><title>CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases</title><source>Elsevier ScienceDirect Journals</source><creator>Karimian, Ansar ; Gorjizadeh, Negar ; Alemi, Forough ; Asemi, Zatollah ; Azizian, Khalil ; Soleimanpour, Jafar ; Malakouti, Faezeh ; Targhazeh, Niloufar ; Majidinia, Maryam ; Yousefi, Bahman</creator><creatorcontrib>Karimian, Ansar ; Gorjizadeh, Negar ; Alemi, Forough ; Asemi, Zatollah ; Azizian, Khalil ; Soleimanpour, Jafar ; Malakouti, Faezeh ; Targhazeh, Niloufar ; Majidinia, Maryam ; Yousefi, Bahman</creatorcontrib><description>CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
[Display omitted]</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2020.118165</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Alzheimer disease ; Alzheimer's disease ; Amino acid sequence ; CRISPR ; CRISPR-associated endonuclease 9 ; CRISPR-Cas systems ; CRISPR/Cas9 ; Deoxyribonucleic acid ; DNA ; Editing ; Gene therapy ; genome ; Genome editing ; Genomes ; Health services ; Huntington's disease ; Huntingtons disease ; Medical treatment ; Movement disorders ; Neurodegenerative diseases ; Neurological diseases ; Neurological disorders ; Nuclease ; Nucleotide sequence ; nucleotide sequences ; Parkinson disease ; Parkinson's disease ; Technology ; Viruses</subject><ispartof>Life sciences (1973), 2020-10, Vol.259, p.118165-118165, Article 118165</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright Elsevier BV Oct 15, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-f0528d420a25d814ee792f90ceed65836e837d641155cecad1ffb096546998dd3</citedby><cites>FETCH-LOGICAL-c391t-f0528d420a25d814ee792f90ceed65836e837d641155cecad1ffb096546998dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lfs.2020.118165$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids></links><search><creatorcontrib>Karimian, Ansar</creatorcontrib><creatorcontrib>Gorjizadeh, Negar</creatorcontrib><creatorcontrib>Alemi, Forough</creatorcontrib><creatorcontrib>Asemi, Zatollah</creatorcontrib><creatorcontrib>Azizian, Khalil</creatorcontrib><creatorcontrib>Soleimanpour, Jafar</creatorcontrib><creatorcontrib>Malakouti, Faezeh</creatorcontrib><creatorcontrib>Targhazeh, Niloufar</creatorcontrib><creatorcontrib>Majidinia, Maryam</creatorcontrib><creatorcontrib>Yousefi, Bahman</creatorcontrib><title>CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases</title><title>Life sciences (1973)</title><description>CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
[Display omitted]</description><subject>Alzheimer disease</subject><subject>Alzheimer's disease</subject><subject>Amino acid sequence</subject><subject>CRISPR</subject><subject>CRISPR-associated endonuclease 9</subject><subject>CRISPR-Cas systems</subject><subject>CRISPR/Cas9</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Editing</subject><subject>Gene therapy</subject><subject>genome</subject><subject>Genome editing</subject><subject>Genomes</subject><subject>Health services</subject><subject>Huntington's disease</subject><subject>Huntingtons disease</subject><subject>Medical treatment</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neurological diseases</subject><subject>Neurological disorders</subject><subject>Nuclease</subject><subject>Nucleotide sequence</subject><subject>nucleotide sequences</subject><subject>Parkinson disease</subject><subject>Parkinson's disease</subject><subject>Technology</subject><subject>Viruses</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkUFrFDEUx4MouFY_gLcBL15m-5JJMgk9yWK1UGhZ7TnE5EWzzE62SWah394s66kHewov_P5_eO9HyEcKawpUXu7WUyhrBqzNVFEpXpEVVaPuQQ70NVkBMN4PDMRb8q6UHQAIMQ4rst1sb37cby83tuhuTkecuvoHsz3gUqPrcrK-CymfPrua0dY9zrVLoZtxycnjb5wbXeMROx8L2oLlPXkT7FTww7_3gjxcf_25-d7f3n272Xy57d2gae0DCKY8Z2CZ8IpyxFGzoMEheinUIFENo5ecUiEcOutpCL9AS8Gl1sr74YJ8PvcecnpcsFSzj8XhNNkZ01IMExy4ppyrl1HO9Ki45LKhn56hu7TkuS3SCkHw1jfSRtEz5XIqJWMwhxz3Nj8ZCuYkxOxME2JOQsxZSMtcnTPYjnKMmE1xEWeHPmZ01fgU_5P-C3A9kXw</recordid><startdate>20201015</startdate><enddate>20201015</enddate><creator>Karimian, Ansar</creator><creator>Gorjizadeh, Negar</creator><creator>Alemi, Forough</creator><creator>Asemi, Zatollah</creator><creator>Azizian, Khalil</creator><creator>Soleimanpour, Jafar</creator><creator>Malakouti, Faezeh</creator><creator>Targhazeh, Niloufar</creator><creator>Majidinia, Maryam</creator><creator>Yousefi, Bahman</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20201015</creationdate><title>CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases</title><author>Karimian, Ansar ; Gorjizadeh, Negar ; Alemi, Forough ; Asemi, Zatollah ; Azizian, Khalil ; Soleimanpour, Jafar ; Malakouti, Faezeh ; Targhazeh, Niloufar ; Majidinia, Maryam ; Yousefi, Bahman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-f0528d420a25d814ee792f90ceed65836e837d641155cecad1ffb096546998dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer disease</topic><topic>Alzheimer's disease</topic><topic>Amino acid sequence</topic><topic>CRISPR</topic><topic>CRISPR-associated endonuclease 9</topic><topic>CRISPR-Cas systems</topic><topic>CRISPR/Cas9</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Editing</topic><topic>Gene therapy</topic><topic>genome</topic><topic>Genome editing</topic><topic>Genomes</topic><topic>Health services</topic><topic>Huntington's disease</topic><topic>Huntingtons disease</topic><topic>Medical treatment</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neurological diseases</topic><topic>Neurological disorders</topic><topic>Nuclease</topic><topic>Nucleotide sequence</topic><topic>nucleotide sequences</topic><topic>Parkinson disease</topic><topic>Parkinson's disease</topic><topic>Technology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karimian, Ansar</creatorcontrib><creatorcontrib>Gorjizadeh, Negar</creatorcontrib><creatorcontrib>Alemi, Forough</creatorcontrib><creatorcontrib>Asemi, Zatollah</creatorcontrib><creatorcontrib>Azizian, Khalil</creatorcontrib><creatorcontrib>Soleimanpour, Jafar</creatorcontrib><creatorcontrib>Malakouti, Faezeh</creatorcontrib><creatorcontrib>Targhazeh, Niloufar</creatorcontrib><creatorcontrib>Majidinia, Maryam</creatorcontrib><creatorcontrib>Yousefi, Bahman</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karimian, Ansar</au><au>Gorjizadeh, Negar</au><au>Alemi, Forough</au><au>Asemi, Zatollah</au><au>Azizian, Khalil</au><au>Soleimanpour, Jafar</au><au>Malakouti, Faezeh</au><au>Targhazeh, Niloufar</au><au>Majidinia, Maryam</au><au>Yousefi, Bahman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases</atitle><jtitle>Life sciences (1973)</jtitle><date>2020-10-15</date><risdate>2020</risdate><volume>259</volume><spage>118165</spage><epage>118165</epage><pages>118165-118165</pages><artnum>118165</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
[Display omitted]</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.lfs.2020.118165</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0024-3205 |
| ispartof | Life sciences (1973), 2020-10, Vol.259, p.118165-118165, Article 118165 |
| issn | 0024-3205 1879-0631 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2429784646 |
| source | Elsevier ScienceDirect Journals |
| subjects | Alzheimer disease Alzheimer's disease Amino acid sequence CRISPR CRISPR-associated endonuclease 9 CRISPR-Cas systems CRISPR/Cas9 Deoxyribonucleic acid DNA Editing Gene therapy genome Genome editing Genomes Health services Huntington's disease Huntingtons disease Medical treatment Movement disorders Neurodegenerative diseases Neurological diseases Neurological disorders Nuclease Nucleotide sequence nucleotide sequences Parkinson disease Parkinson's disease Technology Viruses |
| title | CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A48%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRISPR/Cas9%20novel%20therapeutic%20road%20for%20the%20treatment%20of%20neurodegenerative%20diseases&rft.jtitle=Life%20sciences%20(1973)&rft.au=Karimian,%20Ansar&rft.date=2020-10-15&rft.volume=259&rft.spage=118165&rft.epage=118165&rft.pages=118165-118165&rft.artnum=118165&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2020.118165&rft_dat=%3Cproquest_cross%3E2429784646%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2505414471&rft_id=info:pmid/&rft_els_id=S0024320520309176&rfr_iscdi=true |